Trials / Recruiting
RecruitingNCT06653322
A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HR-1703 | HR-1703 will be administered by SC injection. |
| DRUG | Placebo | Matching Placebo will be administered by the SC injection. |
Timeline
- Start date
- 2024-11-21
- Primary completion
- 2027-09-01
- Completion
- 2027-12-01
- First posted
- 2024-10-22
- Last updated
- 2025-12-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06653322. Inclusion in this directory is not an endorsement.